Ulthera, Inc., a Mesa, Ariz.-based developer of a ultrasound device approved by the FDA for aesthetics, raised $10.5m in Series C venture funding.
The round was led by New Enterprise Associates (NEA), with participation from funds managed by Apposite Capital LLP.
As also stated by President and CEO Matthew E. Likens, Ulthera intends to use the funds to continue to develop its platform technology, continue to invest in product development and expand the organization.
Founded in 2004, the company has developed an ultrasound device (the Ulthera® System) to be used as a non-invasive face and neck treatment with a specific indication for eyebrow lift.
The system has been available in Europe and Asia since 2008 through a network of distributors outside the U.S. Within the U.S. the company operates through its direct sales and marketing organization focused on plastic surgeons, facial plastic surgeons and dermatologists.